LLNL Biomedical Licensee Collaborating With Two Drug Companies To Advance Treatments For Autoimmune Diseases
February 17, 2023
February 17, 2023
LIVERMORE, California, Feb. 17 -- The U.S. Department of Energy's Lawrence Livermore National Laboratory issued the following news release:
People afflicted with autoimmune diseases may someday receive help through treatments now under development by a Lawrence Livermore National Laboratory (LLNL) licensee and its' collaborations with two major pharmaceutical companies.
In late 2017, LLNL licensed a biomedical technology called nanolipoprotein particles (NLPs), which c . . .
People afflicted with autoimmune diseases may someday receive help through treatments now under development by a Lawrence Livermore National Laboratory (LLNL) licensee and its' collaborations with two major pharmaceutical companies.
In late 2017, LLNL licensed a biomedical technology called nanolipoprotein particles (NLPs), which c . . .